EyePoint Pharmaceuticals (FRA:PV3B) Total Long-Term Assets : €10.62 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. EyePoint Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Mar. 2024 was €10.62 Mil.

EyePoint Pharmaceuticals Total Long-Term Assets Historical Data

The historical data trend for EyePoint Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Total Long-Term Assets Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Assets

Get a 7-Day Free Trial

28.13

23.51

22.68

7.13

9.52

EyePoint Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Long-Term Assets	Get a 7-Day Free Trial															7.97	7.88	9.26	9.52	10.62

EyePoint Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

EyePoint Pharmaceuticals Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (FRA:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (FRA:PV3B) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (FRA:PV3B) Headlines

No Headlines